

# List of figures, tables and boxes

## Chapter I

### Figures

Figure 1.1	Leading causes of disease burden in DALYs in 2000 and 2016 globally	34
Figure 1.2	Leading causes of death in 2000 and 2016 globally	34
Figure 1.3	Global burden of disease ranking, 1990 and 2017	35
Figure 1.4	The distinct policy domains of public health	37
Figure 1.5	Policy intersections between distinct levels	38

### Boxes

Box 1.1	WHO–WIPO–WTO technical symposia	32
Box 1.2	The disability-adjusted life year (DALY)	33
Box 1.3	Health and medical technologies: fundamental concepts	39

## Chapter II

### Figures

Figure 2.1	Key challenges in implementing national action plans	52
Figure 2.2	Stewardship, innovation and access: a delicate balance of conflicting goals	52
Figure 2.3	Illustration of terms of patent protection and regulatory exclusivities	61
Figure 2.4	Growth of the top four technology fields, 2000–2019	79
Figure 2.5	PCT applications in the field of medical technology, including pharmaceuticals, 2000–2019	79
Figure 2.6	Main countries of origin of PCT publications in the field of medical technology, including pharmaceuticals, 2000–2019	80

### Tables

Table 2.1	Information available in MedsPaL and Pat-INFORMED	75
Table 2.2	Examples of search parameters for pharmaceutical substances	77
Table 2.3	Number of GATS commitments	101
Table 2.4	Coverage in the health sector by parties to the WTO GPA	104

### Boxes

Box 2.1	Selected reports on access to medicines and R&D	47
Box 2.2	The Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property	50
Box 2.3	CRISPR-Cas9 gene-editing technology	58
Box 2.4	CAR T-cell therapy	58
Box 2.5	Selected types of US regulatory exclusivity	60
Box 2.6	The Paris Convention	64
Box 2.7	TRIPS and public health: key milestones	65
Box 2.8	The Patent Cooperation Treaty	67
Box 2.9	Societal and moral values in the patent system	69

Box 2.10	WIPO Standing Committee on the Law of Patents	73
Box 2.11	Selected databases	75
Box 2.12	The example of colchicine	83
Box 2.13	The Madrid System for the International Registration of Marks	84
Box 2.14	Artificial intelligence and health	89
Box 2.15	Definition of flexibilities according to WIPO	92
Box 2.16	TRIPS flexibilities highlighted in the GSPA-PHI and Road Map for Access to Medicines, Vaccines and Other Health Products, 2019–2023	92
Box 2.17	The example of Cambodia: an LDC's terms of accession to the WTO	95
Box 2.18	Merger control in the European Union	97
Box 2.19	Antimicrobial resistance in the SPS Committee	100
Box 2.20	Product patents and access to innovative medicines in a post-TRIPS era	110
Box 2.21	The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity (Nagoya Protocol)	115

## Chapter III

### Figures

Figure 3.1	Approvals of medicines by the US Food & Drug Administration, 1944–2019	135
Figure 3.2	Global R&D expenditures, PCT international application publications on pharmaceuticals and novel drug approvals in the United States, 2004–2019	135
Figure 3.3	Novel drug approvals, percentage with orphan designation and R&D expenditure as percentage of sales, 1999–2019	136
Figure 3.4	Patent publications by technology: performance by sector, income group and world, 1980–2017	137
Figure 3.5	Top countries of origin of PCT publications in the field of pharmaceuticals, 1996–2019	139
Figure 3.6	The innovation cycle	144
Figure 3.7	Timeline of the discovery of different antibiotic classes in clinical use	153
Figure 3.8	Number and sales values of PRVs	160

### Tables

Table 3.1	PRVs issued, 2009–2019	159
Table 3.2	Pharmaceutical industry centres dedicated to NTDs R&D	164
Table 3.3	IP issues that may arise at each stage of the product development pipeline	167
Table 3.4	The different roles of patents in the medical devices industry and the pharmaceutical industry	169
Table 3.5	Summary of benefit-sharing options under SMTA 2	182

### Boxes

Box 3.1	IP and licensing in the discovery of insulin	134
Box 3.2	Adaptation of medical devices to developing-country needs – the example of portable electrocardiographs	141
Box 3.3	Monoclonal antibodies	142
Box 3.4	New innovation models in practice: tailoring a meningitis vaccine for Africa	146

Box 3.5	Advance market commitments in vaccines	147
Box 3.6	European Medicines Agency makes available clinical trials data	150
Box 3.7	Initiatives to revitalize the antimicrobial pipeline	154
Box 3.8	WHO R&D Blueprint for Action to Prevent Epidemics: priority list as at February 2018	155
Box 3.9	2012 CEWG report: key recommendations	155
Box 3.10	Unitaid	157
Box 3.11	Examples of prize schemes	157
Box 3.12	Examples of successful product development partnerships	162
Box 3.13	Patenting products of nature – the <i>Myriad</i> case	170
Box 3.14	Examples of drug-device combinations	172
Box 3.15	How India defines and applies patentability criteria	174
Box 3.16	Second use patents: the case of fluoxetine	175
Box 3.17	WIPO Patent Search Report on PIP-Related Patents and Patent Applications	181

## Chapter IV

### Figures

Figure 4.1	The WHO Health System Framework	193
Figure 4.2	The three dimensions of universal health coverage	194
Figure 4.3	Ensuring access along the value chain of medicines and health products	195
Figure 4.4	Local production and access to essential medical products: a framework for improving public health	211
Figure 4.5	Sales revenue per year of generic and originator ARVs in LMICs	218
Figure 4.6	Sales quantities per year of generic and originator ARVs in LMICs	219
Figure 4.7	Challenges in access to AMR-related technologies in LMICs	220
Figure 4.8	Detention of generic medicines in transit by EU Customs	251
Figure 4.9	Evolution of IP chapters in FTAs: developments from 2000 to 2019	257
Figure 4.10	Imports of health-related products 1995–2018, by value (in US\$ million) and compound growth rates, 2018	264
Figure 4.11	Per capita imports of pharmaceutical formulations 1995–2018	267
Figure 4.12	Tariffs on health-related products: simple applied average versus WTO simple bound average rates, by product category, 2018	268

### Tables

Table 4.1	Selected country experiences with compulsory licences and government-use licences	239
Table 4.2	Comparison of expected patent expiry dates and dates of SPC expiry in France, for selected medicines on the WHO EML	249
Table 4.3	Provisions in selected FTAs with a bearing on access and innovation in the pharmaceutical sector	253
Table 4.4	Public-health-related products	263
Table 4.5	International trade in health-related products: share of main importers, 2018	264
Table 4.6	International trade in health-related products: share of main exporters, 2018	265
Table 4.7	Net exporters of pharmaceutical products (categories A1, A2, A3), average 2016–2018	266

Table 4.8	Net importers of pharmaceutical products (categories A1, A2, A3), average 2016–2018	266
Table 4.9	Share of health product imports in total national imports, 2018	267
<b>Boxes</b>		
Box 4.1	The US Hatch-Waxman Act as a supply-side measure to encourage generic competition	197
Box 4.2	Price control and reference prices to reduce prices of medicines in Colombia	199
Box 4.3	Examples of databases of medicines prices	202
Box 4.4	Differential packaging	203
Box 4.5	Authorized generics	203
Box 4.6	The WHO Model List of Essential Medicines	205
Box 4.7	Cost reduction/improvements in value for money in the health-care sector through centralized procurement: the example of Ecuador	207
Box 4.8	Examples of European pooled procurement initiatives: the Beneluxa Initiative and the Joint Procurement Mechanisms	208
Box 4.9	Developing local production capacities in Ghana: support measures and challenges	210
Box 4.10	Europe: tightening controls to guarantee the safety of medical devices	212
Box 4.11	WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products	216
Box 4.12	Innovative Medicines for Tuberculosis (iM4TB) Foundation	221
Box 4.13	WHO, Pricing of Cancer Medicines and its Impacts (2019)	222
Box 4.14	Access to insulin	223
Box 4.15	Buyers' clubs	225
Box 4.16	Gavi, the Vaccine Alliance	226
Box 4.17	Precision medicine and the patentability of diagnostic and treatment methods	231
Box 4.18	Guidelines for the examination of pharmaceutical patents: developing a public health perspective	232
Box 4.19	The US Patent Trial and Appeal Board	234
Box 4.20	Government-use licences: efavirenz and lopinavir/ritonavir in Thailand	236
Box 4.21	Government-use licences: hepatitis C treatment in Malaysia	237
Box 4.22	Compulsory licences as a litigation tool	239
Box 4.23	Case study on supply of ARVs to Rwanda	243
Box 4.24	The Medicines Patent Pool	245
Box 4.25	Access to Medicine Index	246
Box 4.26	Cases under IIAs and FTAs	260
Box 4.27	The emergence of global value chains	265
Box 4.28	How tariff reductions can save human lives: the example of mosquito nets	268
Box 4.29	Sectoral tariff negotiations in the GATT and the WTO	269
Box 4.30	The WTO Trade Facilitation Agreement	270
Box 4.31	Competition investigation into strategic patenting – cases from South Africa	271
Box 4.32	Action against sham litigation in the pharmaceutical sector in Brazil	272
Box 4.33	Landmark reverse patent settlement ruling by the Supreme Court of the United States and subsequent developments	272

Box 4.34	The European Union's Guidelines on Technology Transfer Agreements, monitoring and enforcement against reverse patent settlements in the pharmaceutical sector	273
Box 4.35	Competition law enforcement against a reverse patent settlement in the Republic of Korea	273
Box 4.36	Abuse of dominance in South Africa	273
Box 4.37	Applying competition law to generic manufacturers	275
Box 4.38	General approaches to "excessive pricing" in domestic laws	275
Box 4.39	Examples of "excessive pricing" cases concerning pharmaceuticals	275
Box 4.40	Jurisprudence on competition authority scrutiny to enable competition through off-label use	276
Box 4.41	Hospital merger in Brazil	276
Box 4.42	The 2019 Health Market Inquiry of the Competition Commission of South Africa	277

## Annexes

### Tables

Resolutions of the UN General Assembly and UN Human Rights Council	
Key Reports of the UN Special Rapporteur on the Right to Health	292
Selected Resolutions and Decisions of the World Health Assembly	298
Special Compulsory Licences for Export of Medicines	302